Generali Asset Management SPA SGR Invests $3.01 Million in United Therapeutics Co. (NASDAQ:UTHR)

Generali Asset Management SPA SGR acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,524 shares of the biotechnology company's stock, valued at approximately $3,008,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics during the fourth quarter worth about $25,000. Brooklyn Investment Group acquired a new position in shares of United Therapeutics in the third quarter valued at approximately $33,000. MassMutual Private Wealth & Trust FSB increased its stake in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after buying an additional 58 shares during the period. Jones Financial Companies Lllp lifted its holdings in United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after buying an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in United Therapeutics in the 4th quarter valued at approximately $131,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

UTHR traded up $6.87 on Monday, reaching $319.86. The company's stock had a trading volume of 376,139 shares, compared to its average volume of 446,565. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The business's 50 day moving average is $345.10 and its 200 day moving average is $357.05. The stock has a market cap of $14.37 billion, a price-to-earnings ratio of 14.05, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

Remove Ads

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter last year, the company earned $4.36 earnings per share. As a group, research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 80,255 shares of company stock valued at $28,995,021. Insiders own 11.90% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on UTHR. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.